Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Jordan, Suzana; H. W. Distler, Jörg; Maurer, Britta; Huscher, Dörte; M. van Laar, Jacob; Allanore, Yannick; Distler, Oliver; Airo, Paolo; José Alegre Sancho, Juan; P Ananjeva, L; Ancuța, Codrina; Aringer, Martin; Balbir‐Gurman, Alexandra; Paolo Cantatore, Francesco; Caramaschi, Paola; Chatelus, Emmanuel; Codullo, Veronica; Farge, Dominique; Foti, Rosario; Gabrielli, Armando; Henes, Jörg; Herrgott, Ilka; Iannone, Florenzo; Ingegnoli, Francesca; Loyo, Esthela; Matucci‐Cerinic, Marco; Ahmed Abdel Atty Mohamed, Walid; Müller-Ladner, Ulf; Palm, Øyvind; Popa, Sergiu; Riemekasten, Gabriela; Rednic, Simona; Rosato, Edoardo; Saracco, Marta; Scheja, A; Smith, Vanessa; Mihai, Carina; Szucs, Gabriela; Tomšič, Matija; Valentini, Gabriele; A. Walker, Ulrich; Westhovens, R; Yavuz, Şule; Zénone, Thierry

doi:10.1136/annrheumdis-2013-204522

Public

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Published in Annals of the Rheumatic Diseases • Jan 17, 2014

Authors:

Suzana Jordan

Jörg H. W. Distler

Britta Maurer

Abstract

OBJECTIVES: To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to the European Scleroderma Trial and Research (EUSTAR) cohort and using a nested case-control design. METHODS: Inclusion criteria were fulfilment of American College of...

Subject

Medicine

Internal medicine

Scleroderma (fungus)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!